Hemophilia Gene Therapy Industry Research Report 2024
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
According to APO Research, The global Hemophilia Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Hemophilia Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemophilia Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Gene Therapy.
The Hemophilia Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hemophilia Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
- Hemophilia A
- Hemophilia B
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Hemophilia Gene Therapy by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Hemophilia A
2.2.3 Hemophilia B
2.3 Hemophilia Gene Therapy by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hemophilia A Gene Therapy
2.3.3 Hemophilia B Gene Therapy
2.4 Assumptions and Limitations
3 HEMOPHILIA GENE THERAPY BREAKDOWN DATA BY TYPE
3.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2019-2024)
3.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2025-2030)
4 HEMOPHILIA GENE THERAPY BREAKDOWN DATA BY APPLICATION
4.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2019-2024)
4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Hemophilia Gene Therapy Market Perspective (2019-2030)
5.2 Global Hemophilia Gene Therapy Growth Trends by Region
5.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Hemophilia Gene Therapy Historic Market Size by Region (2019-2024)
5.2.3 Hemophilia Gene Therapy Forecasted Market Size by Region (2025-2030)
5.3 Hemophilia Gene Therapy Market Dynamics
5.3.1 Hemophilia Gene Therapy Industry Trends
5.3.2 Hemophilia Gene Therapy Market Drivers
5.3.3 Hemophilia Gene Therapy Market Challenges
5.3.4 Hemophilia Gene Therapy Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Hemophilia Gene Therapy Players by Revenue
6.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2019-2024)
6.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2019-2024)
6.2 Global Hemophilia Gene Therapy Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Hemophilia Gene Therapy Head office and Area Served
6.4 Global Hemophilia Gene Therapy Players, Product Type & Application
6.5 Global Hemophilia Gene Therapy Players, Date of Enter into This Industry
6.6 Global Hemophilia Gene Therapy Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Hemophilia Gene Therapy Market Size (2019-2030)
7.2 North America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Hemophilia Gene Therapy Market Size by Country (2019-2024)
7.4 North America Hemophilia Gene Therapy Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Hemophilia Gene Therapy Market Size (2019-2030)
8.2 Europe Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Hemophilia Gene Therapy Market Size by Country (2019-2024)
8.4 Europe Hemophilia Gene Therapy Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2019-2030)
9.2 Asia-Pacific Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2019-2024)
9.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Hemophilia Gene Therapy Market Size (2019-2030)
10.2 Latin America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Hemophilia Gene Therapy Market Size by Country (2019-2024)
10.4 Latin America Hemophilia Gene Therapy Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2019-2030)
11.2 Middle East & Africa Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2019-2024)
11.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Spark Therapeutics
12.1.1 Spark Therapeutics Company Information
12.1.2 Spark Therapeutics Business Overview
12.1.3 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
12.1.5 Spark Therapeutics Recent Developments
12.2 Ultragenyx
12.2.1 Ultragenyx Company Information
12.2.2 Ultragenyx Business Overview
12.2.3 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
12.2.5 Ultragenyx Recent Developments
12.3 Shire PLC
12.3.1 Shire PLC Company Information
12.3.2 Shire PLC Business Overview
12.3.3 Shire PLC Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
12.3.5 Shire PLC Recent Developments
12.4 Sangamo Therapeutics
12.4.1 Sangamo Therapeutics Company Information
12.4.2 Sangamo Therapeutics Business Overview
12.4.3 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
12.4.5 Sangamo Therapeutics Recent Developments
12.5 Bioverativ
12.5.1 Bioverativ Company Information
12.5.2 Bioverativ Business Overview
12.5.3 Bioverativ Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
12.5.5 Bioverativ Recent Developments
12.6 BioMarin
12.6.1 BioMarin Company Information
12.6.2 BioMarin Business Overview
12.6.3 BioMarin Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
12.6.5 BioMarin Recent Developments
12.7 uniQure
12.7.1 uniQure Company Information
12.7.2 uniQure Business Overview
12.7.3 uniQure Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
12.7.5 uniQure Recent Developments
12.8 Freeline Therapeutics
12.8.1 Freeline Therapeutics Company Information
12.8.2 Freeline Therapeutics Business Overview
12.8.3 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
12.8.5 Freeline Therapeutics Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Hemophilia Gene Therapy by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Hemophilia A
2.2.3 Hemophilia B
2.3 Hemophilia Gene Therapy by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hemophilia A Gene Therapy
2.3.3 Hemophilia B Gene Therapy
2.4 Assumptions and Limitations
3 HEMOPHILIA GENE THERAPY BREAKDOWN DATA BY TYPE
3.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2019-2024)
3.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2025-2030)
4 HEMOPHILIA GENE THERAPY BREAKDOWN DATA BY APPLICATION
4.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2019-2024)
4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Hemophilia Gene Therapy Market Perspective (2019-2030)
5.2 Global Hemophilia Gene Therapy Growth Trends by Region
5.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Hemophilia Gene Therapy Historic Market Size by Region (2019-2024)
5.2.3 Hemophilia Gene Therapy Forecasted Market Size by Region (2025-2030)
5.3 Hemophilia Gene Therapy Market Dynamics
5.3.1 Hemophilia Gene Therapy Industry Trends
5.3.2 Hemophilia Gene Therapy Market Drivers
5.3.3 Hemophilia Gene Therapy Market Challenges
5.3.4 Hemophilia Gene Therapy Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Hemophilia Gene Therapy Players by Revenue
6.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2019-2024)
6.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2019-2024)
6.2 Global Hemophilia Gene Therapy Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Hemophilia Gene Therapy Head office and Area Served
6.4 Global Hemophilia Gene Therapy Players, Product Type & Application
6.5 Global Hemophilia Gene Therapy Players, Date of Enter into This Industry
6.6 Global Hemophilia Gene Therapy Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Hemophilia Gene Therapy Market Size (2019-2030)
7.2 North America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Hemophilia Gene Therapy Market Size by Country (2019-2024)
7.4 North America Hemophilia Gene Therapy Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Hemophilia Gene Therapy Market Size (2019-2030)
8.2 Europe Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Hemophilia Gene Therapy Market Size by Country (2019-2024)
8.4 Europe Hemophilia Gene Therapy Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2019-2030)
9.2 Asia-Pacific Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2019-2024)
9.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Hemophilia Gene Therapy Market Size (2019-2030)
10.2 Latin America Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Hemophilia Gene Therapy Market Size by Country (2019-2024)
10.4 Latin America Hemophilia Gene Therapy Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2019-2030)
11.2 Middle East & Africa Hemophilia Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2019-2024)
11.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Spark Therapeutics
12.1.1 Spark Therapeutics Company Information
12.1.2 Spark Therapeutics Business Overview
12.1.3 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
12.1.5 Spark Therapeutics Recent Developments
12.2 Ultragenyx
12.2.1 Ultragenyx Company Information
12.2.2 Ultragenyx Business Overview
12.2.3 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
12.2.5 Ultragenyx Recent Developments
12.3 Shire PLC
12.3.1 Shire PLC Company Information
12.3.2 Shire PLC Business Overview
12.3.3 Shire PLC Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
12.3.5 Shire PLC Recent Developments
12.4 Sangamo Therapeutics
12.4.1 Sangamo Therapeutics Company Information
12.4.2 Sangamo Therapeutics Business Overview
12.4.3 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
12.4.5 Sangamo Therapeutics Recent Developments
12.5 Bioverativ
12.5.1 Bioverativ Company Information
12.5.2 Bioverativ Business Overview
12.5.3 Bioverativ Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
12.5.5 Bioverativ Recent Developments
12.6 BioMarin
12.6.1 BioMarin Company Information
12.6.2 BioMarin Business Overview
12.6.3 BioMarin Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
12.6.5 BioMarin Recent Developments
12.7 uniQure
12.7.1 uniQure Company Information
12.7.2 uniQure Business Overview
12.7.3 uniQure Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
12.7.5 uniQure Recent Developments
12.8 Freeline Therapeutics
12.8.1 Freeline Therapeutics Company Information
12.8.2 Freeline Therapeutics Business Overview
12.8.3 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2019-2024)
12.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
12.8.5 Freeline Therapeutics Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
